We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
-17%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$1.05B
AUM Growth
-$223M
(-17%)
Cap. Flow
+$34.7M
Cap. Flow
% of AUM
3.3%
Top 10 Holdings %
Top 10 Hldgs %
48.18%
Holding
82
New
3
Increased
31
Reduced
13
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tactile Systems Technology
TCMD
|
+$26.6M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$23.1M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$21.2M |
| 4 |
Pliant Therapeutics
PLRX
|
+$19.5M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$146M |
| 2 |
ABCM
Abcam PLC
ABCM
|
+$17.4M |
| 3 |
Krystal Biotech
KRYS
|
+$11.9M |
| 4 |
Halozyme
HALO
|
+$11.1M |
| 5 |
Orthofix Medical
OFIX
|
+$10.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.63% |
| 2 | Communication Services | 4.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$425M
| $72.1M | 6.85% |
1,494,039
-6,090
| -0.4% | -$362K |
|
2
AtriCure
ATRC
$1.92B
| $65.2M | 6.2% |
1,489,407
+27,772
| +2% | +$1.35M |
|
3
SI-BONE Inc
SIBN
$788M
| $53.6M | 5.09% |
2,524,093
+409,264
| +19% | +$9.48M |
|
|
KRTX
4
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $51.3M | 4.87% |
303,137
+94,391
| +45% | +$17.7M |
|
|
5
Pliant Therapeutics
PLRX
$64.4M
| $50.9M | 4.83% |
2,933,260
+1,123,084
| +62% | +$19.5M |
|
6
Crinetics Pharmaceuticals
CRNX
$8.84B
| $47.1M | 4.47% |
1,583,329
+26,107
| +2% | +$538K |
|
|
MODN
7
DELISTED
MODEL N, INC.
MODN
| $46M | 4.37% |
1,886,218
+20,693
| +1% | +$614K |
|
|
BCYC
8
Bicycle Therapeutics
BCYC
$269M
| $41.6M | 3.95% |
2,070,853
+331,404
| +19% | +$7.58M |
|
|
9
Ultragenyx Pharmaceutical
RARE
$2.45B
| $40.1M | 3.81% |
1,125,032
+535,069
| +91% | +$21.2M |
|
10
Alphatec Holdings
ATEC
$1.46B
| $39.3M | 3.74% |
3,033,541
+61,664
| +2% | +$966K |
|
11
NeoGenomics
NEO
$1.96B
| $37.3M | 3.54% |
3,028,913
+336,856
| +13% | +$5.01M |
|
|
FNA
12
DELISTED
Paragon 28, Inc.
FNA
| $34.4M | 3.26% |
2,737,878
+680,571
| +33% | +$10.3M |
|
13
Transmedics
TMDX
$2.64B
| $33.8M | 3.21% |
618,100
+240,636
| +64% | +$17.3M |
|
|
14
Tandem Diabetes Care
TNDM
$1.34B
| $29.9M | 2.84% |
1,440,966
+840,199
| +140% | +$23.1M |
|
15
Health Catalyst
HCAT
$154M
| $29.7M | 2.82% |
2,930,144
+389,185
| +15% | +$4.65M |
|
|
16
Tactile Systems Technology
TCMD
$635M
| $29.1M | 2.76% |
2,071,419
+1,360,074
| +191% | +$26.6M |
|
|
17
Orthofix Medical
OFIX
$477M
| $23.8M | 2.26% |
1,852,438
-606,691
| -25% | -$10.9M |
|
|
PHLT
18
DELISTED
Performant Healthcare Inc
PHLT
| $21.2M | 2.01% |
9,378,296
+128,613
| +1% | +$326K |
|
19
Xenon Pharmaceuticals
XENE
$6.06B
| $20.6M | 1.95% |
602,070
+263,424
| +78% | +$9.85M |
|
20
TELA Bio
TELA
$32.7M
| $19.8M | 1.88% |
2,480,264
+754,764
| +44% | +$7.01M |
|
21
OptimizeRx
OPRX
$114M
| $19.3M | 1.84% |
2,486,047
+614,248
| +33% | +$6.68M |
|
22
Structure Therapeutics
GPCR
$3.41B
| $18.9M | 1.79% |
+374,412
| New | +$12.1M |
|
|
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
| $18M | 1.71% |
321,173
+8,387
| +3% | +$472K |
|
24
Stevanato
STVN
$5.42B
| $17.4M | 1.65% |
584,755
+470,479
| +412% | +$14.7M |
|
25
Zentalis Pharmaceuticals
ZNTL
$337M
| $17M | 1.62% |
848,477
+90,642
| +12% | +$2.3M |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, First Light Asset Management held 82 positions worth $1.05B, down 17% from $1.28B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
First Light Asset Management deployed $34.7M of net new capital in Q3 2023, opening 3 new positions and adding to 31 existing holdings. Its largest new stake was Structure Therapeutics: 374,412 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Communication Services.
On the sell side, the largest reduction was Halozyme, an estimated $11.1M trimmed.
- First Light Asset Management's largest Q3 2023 buy was Structure Therapeutics: 374,412 shares worth $18.9M.
- First Light Asset Management added most to Tactile Systems Technology in Q3 2023, an estimated $26.6M increase.
- First Light Asset Management's biggest Q3 2023 reduction was Halozyme, cutting an estimated $11.1M.
- First Light Asset Management fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $146M.
- First Light Asset Management's ten largest holdings make up 48% of its $1.05B portfolio in Q3 2023.
- First Light Asset Management opened 3 new positions and closed 7 in Q3 2023.
- First Light Asset Management's portfolio value fell 17% quarter-over-quarter to $1.05B.
Based on First Light Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.